(AOF) – Ipsen and Sutro Biopharma announced the signing of an exclusive worldwide licensing agreement for STRO-003. Ipsen obtains exclusive global rights to develop and commercialize STRO-003, an antibody-small molecule conjugate nearing final stages of preclinical development. STRO-003 targets the ROR1 antigen, clinically validated as an antibody-small molecule conjugate target.
STRO-003 targets the ROR1 antigen, clinically validated as an antibody-small molecule conjugate target.
STRO-003 demonstrated efficacy as monotherapy and displayed a satisfactory safety profile during its preclinical development in solid tumors and hematologic malignancies.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
